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Introduction {#sec005}
============

The stress response is an important mechanism that is indispensable for the maintenance of life. Corticotropin-releasing hormone (CRH) is released from the paraventricular nucleus of the hypothalamus under stress and it stimulates the secretion of adrenocorticotropic hormone (ACTH) from the pituitary gland. ACTH acts on the adrenal cortex and promotes the synthesis of glucocorticoid. This system is called the hypothalamic-pituitary-adrenal (HPA) axis \[[@pone.0147817.ref001]\]. In the hippocampus, hypothalamus, and pituitary gland, there are two receptors that interact with cortisol: the glucocorticoid receptor and mineralocorticoid receptor. When cortisol secretion is increased, the composition and secretion of CRH and ACTH is controlled through these receptors, which results in the suppression of cortisol secretion (negative feedback) \[[@pone.0147817.ref002]\]. Dysfunction of the HPA axis causes hippocampal atrophy \[[@pone.0147817.ref003]\] and it is also related to stress-related diseases such as depression, panic disorder, and post-traumatic stress disorder (PTSD) \[[@pone.0147817.ref004]--[@pone.0147817.ref007]\].

CRH is a polypeptide consisting of 41 amino acid residues \[[@pone.0147817.ref008]\]. The CRH family consists of several neuropeptides: CRH, urocortin 1, urocortin 2, and urocortin 3. CRH is primarily responsible for regulating and/or initiating stress responses via activation of the HPA axis \[[@pone.0147817.ref009]\]. Conversely, urocortins play an indispensable role in the recovery response to stress \[[@pone.0147817.ref009]\]. CRH released in the brain activates the sympathetic system and stimulates the cardiovascular system \[[@pone.0147817.ref010]\]. In addition, it stimulates sacral parasympathetic outflow and colonic motility \[[@pone.0147817.ref011]\]. The dysregulation of CRH increases anxiety and depression \[[@pone.0147817.ref012]\].

There are two G protein-coupled receptors for CRH: CRH receptor 1 (CRHR1, CRF~1~ in IUPHAR nomenclature) and CRH receptor 2 (CRHR2, CRF~2~ in IUPHAR nomenclature). CRHR1 is found at a high density in the brain and pituitary gland, while it is found at a low density in the adrenal gland, ovary, and testis \[[@pone.0147817.ref013]--[@pone.0147817.ref016]\]. Other than its expression in the brain, CRHR2 is distributed widely throughout peripheral organs such as the heart, skeletal muscle, intestines, and airway epithelium \[[@pone.0147817.ref017]--[@pone.0147817.ref020]\]. CRH activates both receptors but is more potent at CRHR1. Urocortin 1 can bind both receptors with equal affinity that is 10-fold greater than CRH binding affinity for CRHR1. urocortin and urocortin don't bind to CRHR1, but CRH, urocortin 2 and urocortin 3 all bind to CRHR2 with equal affinity \[[@pone.0147817.ref021]\]. The distribution of these receptors and their binding affinities to endogenous ligands in individuals may reflect individual differences in physiological function.

Irritable bowel syndrome (IBS) is a prototypic functional gastrointestinal disorder \[[@pone.0147817.ref022]\] accompanied by visceral hypersensitivity \[[@pone.0147817.ref023]\], increased gut reactivity \[[@pone.0147817.ref024]\], and altered central processing \[[@pone.0147817.ref025]\] in response to various stressors \[[@pone.0147817.ref026]\]. A previous study demonstrated that mutual and reciprocal interactions between the brain and gut play a major role in the pathophysiology of IBS \[[@pone.0147817.ref027]\]. In IBS patients, the exogenous administration of CRH induced robust colonic motility \[[@pone.0147817.ref024]\]. Electrical stimulation of the rectum induced an increase in motility indices in IBS patients and this response was inhibited by the administration of a CRH antagonist \[[@pone.0147817.ref028]\]. Therefore, dysfunction of CRH signaling is considered to be related to the pathophysiology of IBS.

CRH plays a stimulatory role in the stress response through the activation of CRHR1, while the specific actions of urocortin 2 and urocortin 3 on CRHR2 may be important for dampening the stress response \[[@pone.0147817.ref004]\]. In the brain, CRHR1 stimulation causes anxiety, but CRHR2 stimulation induces anxiolysis. In regard to gut motility, CRHR1 stimulation evokes colonic motility, but CRHR2 stimulation inhibits gastric emptying \[[@pone.0147817.ref012]\]. From these studies, one of the important determinants of the brain-gut interaction in the stress response of IBS patients is signaling via CRHR1 and CRHR2.

The gene encoding *CRHR1* is located on chromosome 17q21.31 and has a length of 51.55 Kb and contains 14 exons. The gene encoding *CRHR2* is located on chromosome 7p14.3 and has a length 48.19Kb and contains 16 exons. There are many reports on the association between gene variants of CRH receptors and stress-related diseases. In *CRHR1*, variation of the gene has been found to be a risk factor for depression after childhood maltreatment \[[@pone.0147817.ref029]--[@pone.0147817.ref033]\]. A polymorphism of *CRHR1* was reported to be related to recurrent major depressive disorder (MDD) \[[@pone.0147817.ref034]\]. In regard to *CRHR2*, gene variation may affect the risk of PTSD in women by attenuating the stress response and reducing symptoms of the disorder \[[@pone.0147817.ref035]\]. A polymorphism in the *CRHR2* gene was also associated with MDD \[[@pone.0147817.ref036]\]. In a previous study from our laboratory, we showed that genetic polymorphisms and haplotypes of *CRHR1* (*rs110402*, *rs242924*, and *rs7209436*) mediate IBS and related bowel patterns \[[@pone.0147817.ref037]\]. However, the association between *CRHR2* genotypes and IBS has not been investigated. Therefore, we hypothesized that gene polymorphisms and/or haplotypes of *CRHR2* may be associated with IBS pathophysiology and negative emotion in IBS patients.

Methods {#sec006}
=======

Subjects {#sec007}
--------

In total, 142 patients (62 males and 80 females) with IBS who were diagnosed at the Department of Psychosomatic Medicine, Tohoku University Hospital, were enrolled in this study (mean age 22.0 ± 0.2 years; range 18--31). Patients with organic diseases were excluded. In addition, 142 healthy volunteers (74 males and 68 females) were recruited at Tohoku University as controls (mean age 22.0 ± 0.2 years; range 19--31). Subjects without any symptoms or signs during a medical interview and physical examination were identified as healthy controls. There was no significant difference in age, sex ratio among the groups.

IBS patients were diagnosed according to the Rome III criteria \[[@pone.0147817.ref038]\]. IBS was defined as recurrent abdominal pain or discomfort for at least 3 days per month in the last 3 months associated with two or more of the following symptoms: improvement with defecation, onset associated with a change in the frequency of defecation, and/or onset associated with a change in the form (appearance) of stools. These criteria were fulfilled for the previous 3 months with symptom onset at least 6 months prior to diagnosis. According to the Rome III criteria, IBS was classified as IBS with diarrhea (D), constipation (C), or mixed symptoms of diarrhea and constipation (M). Unclassified IBS patients were classified as IBS-M. All subjects provided written informed consent and this study was approved by the Tohoku University Ethics Committee. Consecutive patients who agreed to participate in this study were enrolled.

Two hundred and twenty-two of 284 participants' DNA samples were previously reported on polymorphisms of the *CRHR1* polymorphic region \[[@pone.0147817.ref037]\]. There are apparently different from the targeted genes in this study.

SNP selection {#sec008}
-------------

We used Generic Genome Browser in International HapMap Project (<http://hapmap.ncbi.nlm.nih.gov/index.html.en>) to search the allele frequency (minor allele frequency \> 0.15 in Japanese population). Furthermore, we restricted seven candidate genes, which were selected from single nucleotide polymorphisms (SNPs) for genotyping based on previous literature \[[@pone.0147817.ref035],[@pone.0147817.ref036],[@pone.0147817.ref039]\]. The loci of these SNPs were searched from the dbSNP in the National Center for Biotechnology Information (NCBI, <http://www.ncbi.nlm.nih.gov/>), and are shown in **[Fig 1](#pone.0147817.g001){ref-type="fig"}**.

![SNPs of the *CRHR2* gene examined in this study.\
*CRHR2* is located on chromosome 7p14.3. The arrows and the numbers in parentheses indicate the locus of each SNP. *rs2240403* exists in the fourth exon, but six other SNPs exist in intronic regions. These SNPs had a minor allele frequency of \>15% in the Japanese population. A linkage disequilibrium (LD) plot was generated using D′. D′ = 1 indicates complete LD. D′ values \< 1.0 are shown in the respective squares for the SNP pairs, with darker shades of red representing higher levels of LD.](pone.0147817.g001){#pone.0147817.g001}

Genotyping {#sec009}
----------

Peripheral blood was sampled from the forearm vein of each subject with a heparinized syringe. DNA was then extracted from the lymphocytes using a standard protocol \[[@pone.0147817.ref040]\]. The concentration of each DNA was diluted to 0.2 μg/μL. Seven SNPs (*rs4722999*, *rs3779250*, *rs2240403*, *rs2267710*, *rs2190242*, *rs2284217*, *and rs2284220*) in the regulatory region of the *CRHR2* gene were genotyped using real-time polymerase chain reaction (PCR).

We use the CFX-96 Touch^TM^ Real-time PCR Detection System (Bio-Rad Laboratories, Inc., Tokyo, Japan). PCR amplification was carried out using probe/primer sets for SNP genotyping that were purchased from Applied Biosystems, Tokyo, Japan (set of C1617682310 for *rs2240403*, C1587286110 for *rs2190242*, C1596058610 for *rs2284217*, C1596058010 for *rs2284220*, C34646010 for *rs4722999*, C2580980110 for *rs3779250*, and C1587287110 for *rs2267710*). PCR amplification was performed using a total volume of 10 μL consisting of 5 μL TaqMan Genotyping Master Mix, 4.4 μL ddH~2~O, 0.5 μL TaqMan SNP Genotyping Assays, and 0.1 μL DNA. After initial denaturation at 95°C for 10 min, amplification was performed for 40 cycles at 95°C for 15 s and 60°C for 1 min. To determine the positive control, sequence analysis of CRHR2 genes was performed using an ABI 3130 Genetic Analyzer (PE Applied Biosystems, Foster City, CA). All procedures were performed according to the manufacturer\'s instructions.

Evaluation of psychological state {#sec010}
---------------------------------

Participants\' psychological states were rated using the Perceived-Stress Scale (PSS; \[[@pone.0147817.ref041]\], \[[@pone.0147817.ref042]\]), the State-Trait Anxiety Inventory (STAI; \[[@pone.0147817.ref043]\], \[[@pone.0147817.ref044]\]), and the Self-Rating Depression Scale (SDS; \[[@pone.0147817.ref040]\], \[[@pone.0147817.ref045]\]). The Japanese versions of STAI, SDS, and PSS have been validated and their reliability has been confirmed \[[@pone.0147817.ref042]\].

Statistical analysis {#sec011}
--------------------

The frequencies of genotypes, alleles, and haplotypes of the *CRHR2* SNPs were compared between the IBS patients and controls, or between patients with different bowel patterns (normal, constipation, mixed, and diarrhea) using the χ^2^-test. The effects of variation in *CRHR2* SNPs and haplotypes on psychological states between the IBS patients and controls were examined with two-way analysis of variance (ANOVA). The effects of variation in *CRHR2* haplotypes on psychological states were examined with one-way ANOVA. Statistical analyses were performed using SPSS Statistics version 21.0 software (IBM, Inc., New York, NY). We used Haploview \[[@pone.0147817.ref046]\] to determine the LD of the SNPs within the *CRHR2* gene and test for Hardy--Weinberg equilibrium. Results are expressed as the mean ± standard error, and a *P* value \< 0.05 was considered to be significant.

Results {#sec012}
=======

In the 284 samples, genotype distributions were in Hardy--Weinberg equilibrium for all seven SNPs. The genotype frequencies of the SNPs in the IBS group and healthy controls are listed in **[Table 1](#pone.0147817.t001){ref-type="table"}**. The allele frequencies of the SNPs in the IBS group, healthy controls, and the subtypes of IBS patients are listed in **[Table 2](#pone.0147817.t002){ref-type="table"}**.

10.1371/journal.pone.0147817.t001

###### Genotypes frequencies for seven *CRHR2* SNPs in the IBS patients and controls.

![](pone.0147817.t001){#pone.0147817.t001g}

              Controls n (%) n = 142   IBS Patients n (%) n = 142   *P* value(Control vs. IBS)                           
  ----------- ------------------------ ---------------------------- ---------------------------- ----------- ----------- -----------
  rs4722999   CC                       25 (17.6)                    18 (12.7)                    15 (10.6)   23 (16.2)   **0.037**
              CT                       33 (23.2)                    34 (23.9)                    39 (27.5)   47 (33.1)   
              TT                       16 (11.3)                    16 (11.3)                    8 (5.6)     10 (7.0)    
  rs3779250   CC                       27 (19.0)                    21 (14.8)                    16 (11.3)   28 (19.7)   **0.017**
              CT                       32 (22.5)                    31 (21.8)                    38 (26.8)   44 (31.0)   
              TT                       15 (10.6)                    16 (11.3)                    8 (5.6)     8 (5.6)     
  rs2240403   CC                       54 (38.0)                    37 (26.1)                    38 (26.8)   51 (35.9)   0.855
              CT                       18 (12.7)                    30 (21.1)                    24 (16.9)   27 (19.0)   
              TT                       2 (1.4)                      1 (0.7)                      0 (0.0)     2 (1.4)     
  rs2267710   CC                       28 (19.7)                    23 (16.2)                    20 (14.1)   32 (22.5)   0.107
              CT                       33 (23.2)                    32 (22.5)                    35 (24.6)   41 (28.9)   
              TT                       13 (9.2)                     13 (9.2)                     7 (4.9)     7 (4.9)     
  rs2190242   CC                       25 (17.6)                    23 (16.2)                    21 (14.8)   31 (21.8)   0.518
              AC                       38 (26.8)                    30 (21.1)                    30 (21.1)   41 (28.9)   
              AA                       11 (7.7)                     15 (10.6)                    11 (7.7)    8 (5.6)     
  rs2284217   GG                       22 (15.5)                    22 (15.5)                    22 (15.5)   19 (13.4)   0.171
              GA                       37 (26.1)                    42 (29.6)                    24 (16.9)   46 (32.4)   
              AA                       15 (10.6)                    4 (2.8)                      16 (11.3)   15 (10.6)   
  rs2284220   AA                       21 (14.8)                    22 (15.5)                    23 (16.2)   19 (13.4)   0.289
              AG                       37 (26.1)                    41 (28.9)                    23 (16.2)   46 (32.4)   
              GG                       16 (11.3)                    5 (3.5)                      16 (11.3)   15 10.6     

*P* value \< 0.05 were indicated in bold.

10.1371/journal.pone.0147817.t002

###### Allele expression in the controls, IBS patients, and IBS subtypes for seven SNPs of the *CRHR2* gene.

![](pone.0147817.t002){#pone.0147817.t002g}

              Controls     IBS Patients   Total                  
  ----------- ------------ -------------- ------- ---- ---- ---- -----
  rs4722999   C allele -   32             18      9    1    8    50
              C allele +   110            124     32   35   57   234
              T allele -   43             38      7    11   20   81
              T allele +   99             104     34   25   45   203
  rs3779250   C allele -   31             16      6    1    9    47
              C allele +   111            126     35   35   56   237
              T allele -   48             44      10   14   20   92
              T allele +   94             98      31   22   45   192
  rs2240403   C allele -   3              2       0    2    0    5
              C allele +   139            140     41   34   65   279
              T allele -   91             89      26   23   40   180
              T allele +   51             53      15   13   25   104
  rs2267710   C allele -   26             14      5    1    8    40
              C allele +   116            128     36   35   57   244
              T allele -   52             52      12   16   24   104
              T allele +   90             90      29   20   41   180
  rs2190242   C allele -   26             19      4    1    14   45
              C allele +   116            123     37   35   51   239
              A allele -   48             52      11   18   23   100
              A allele +   94             90      30   18   42   184
  rs2284217   G allele -   19             31      8    9    14   50
              G allele +   123            111     33   27   51   234
              A allele -   44             41      7    10   24   85
              A allele +   98             101     34   26   41   199
  rs2284220   A allele -   21             31      8    9    14   52
              A allele +   121            111     33   27   51   132
              G allele -   43             42      7    11   24   85
              G allele +   99             100     34   25   41   199

IBS subtype: C, constipation; M, mixed; D, diarrhea.

We found that *rs4722999* (A) and *rs3779250* (B) were significantly associated with IBS in terms of genotype distribution (*rs4722999*: *P* = 0.037; *rs3779250*: *P* = 0.017) (**[Fig 2](#pone.0147817.g002){ref-type="fig"}**). For these two SNPs, there was no significant difference in the frequency of the minor allele, but the frequency of the major allele was significantly different.

![Difference in genotype of *CRHR2* SNPs between the controls and IBS patients.\
The SNPs *rs4722999* (**A**) and *rs3779250* (**B**) are shown. The SNPs *rs4722999* (*P* = 0.037) and *rs3779250* (*P* = 0.017, χ^2^-test) were significantly different in the IBS patients in comparison with the controls.](pone.0147817.g002){#pone.0147817.g002}

**[Table 3](#pone.0147817.t003){ref-type="table"}**shows the scores of the psychological scales in the controls and IBS patients. There was no significant difference in the test scores for the three psychological scales between the IBS patients and controls.

10.1371/journal.pone.0147817.t003

###### Perceived stress, depression, and anxiety in the controls and IBS patients.

![](pone.0147817.t003){#pone.0147817.t003g}

                 Controls   IBS Patients   P value         
  -------------- ---------- -------------- --------- ----- -------
  PSS            26.7       0.8            28        0.7   0.203
  STAI (state)   44.1       0.8            45.2      0.8   0.361
  STAI (trait)   47.9       0.9            47.5      0.9   0.739
  SDS            39.4       0.7            40.6      0.6   0.23

PSS: Perceived Stress Scale, STAI: State Trait anxiety Inventry, SDS: Self-rating Depression Scale.

**[Fig 3](#pone.0147817.g003){ref-type="fig"}**shows that the three psychological scores were significantly different by *CRHR2* genotype or group (IBS patients vs. controls). According to PSS in *rs2240403*, the IBS patients were significantly higher than the controls (*P* = 0.018), but there was no significant interaction. According to STAI (state) in *rs2190242* in males, there was a significant genotype effect (*P* = 0.046), but there was no significant interaction. According to SDS in *rs2190242* in males and *rs2240403* in females, there was a significant genotype effect (*rs2190242*: *P* = 0.026; *rs2240403*: *P* = 0.031), but there was no significant interaction.

![Psychological scales and *CRHR2* SNPs in IBS patients and controls.\
PSS: two-way ANOVA showed that the IBS patients with *rs2240403* (*P* = 0.018) had significantly higher perceived stress scale scores than the controls. STAI (state): *rs2190242* in males, genotype effect was significant (*P* = 0.046). SDS: *rs2190242* in males and *rs2240403* in females, genotype effect was significant (*rs2190242*: *P* = 0.026; *rs2240403*: *P* = 0.031). In all scale scores, there was no significant group × genotype interaction.](pone.0147817.g003){#pone.0147817.g003}

According to the selection criteria, four SNPs (*rs4722999*, *rs3779250*, *rs2240403*, and *rs2267710*) of *CRHR2* with strong D′ (\>0.90) were in one linkage block, and two SNPs (*rs2284217* and *rs2284220*) with strong pairwise D′ (\>0.90) were in another block (**[Fig 1](#pone.0147817.g001){ref-type="fig"}**). The selection criteria for haplotypes used in the haplotype analyses were adjacent SNPs with pairwise D′ \> 0.90. Haplotype analysis of the IBS group and healthy controls is shown in **[Table 4](#pone.0147817.t004){ref-type="table"}**. We found that three blocks were positively associated with IBS patients (T-C-C-C: *P* = 0.017; T-C-C-T: *P* = 0.017; C-T-C-C: *P* = 0.043). All haplotypes were found more frequently in the IBS patients than in the controls.

10.1371/journal.pone.0147817.t004

###### Haplotype frequencies of the IBS patients and controls in the *CRHR2* gene.

![](pone.0147817.t004){#pone.0147817.t004g}

  Haplotype               Control---Freq   Case---Freq   *P* value
  ----------------------- ---------------- ------------- -----------
  rs4722999---rs2267710                                  
  TTCT                    0.641            0.620         0.806
  CCCC                    0.754            0.852         0.052
  CCTC                    0.359            0.373         0.902
  TTCC                    0.479            0.592         0.074
  TCCC                    0.479            0.627         **0.017**
  CTCT                    0.415            0.514         0.122
  TTTC                    0.155            0.211         0.283
  TTTT                    0.148            0.190         0.429
  CTTT                    0.148            0.190         0.429
  CCTT                    0.148            0.190         0.429
  TCCT                    0.479            0.627         **0.017**
  TCTT                    0.148            0.190         0.429
  CTTC                    0.155            0.211         0.283
  CTCC                    0.437            0.563         **0.043**
  TCTC                    0.176            0.225         0.374
  CCCT                    0.415            0.507         0.153
  rs2284217---rs2284220                                  
  GA                      0.852            0.782         0.167
  AG                      0.690            0.704         0.897
  AA                      0.542            0.493         0.476
  GG                      0.563            0.486         0.235

*P* value \< 0.05 were indicated in bold.

We tested whether the psychological scale scores were different by haplotypes using One-way ANOVA. The result was shown in **[Fig 4](#pone.0147817.g004){ref-type="fig"}**. The psychological scales PSS (A), STAI (state) (B), STAI (trait) (C) and SDS (D) were shown. The carriers with four haplotypes (T-T-T-T, C-T-T-T, C-C-T-T, and T-C-T-T) had significantly lower scores than the others in all psychological scales. The four haplotype carriers were all the same individuals. In addition, in PSS, two haplotypes (C-T-C-T and C-C-C-T) were similarly significant.

![Psychological scale scores and *CRHR2* haplotypes.\
The psychological scales PSS (A), STAI (state) (B), STAI (trait) (C) and SDS (D) were shown. One-way ANOVA showed that the subjects with four haplotypes (T-T-T-T, C-T-T-T, C-C-T-T, and T-C-T-T) had significantly lower score than the others in all psychological scales. The four haplotype carriers were all the same individuals. In addition, in PSS, two haplotypes (C-T-C-T and C-C-C-T) were similarly significant.](pone.0147817.g004){#pone.0147817.g004}

We tested whether the psychological scale scores were different by haplotypes between the IBS patients and controls using two-way ANOVA. The result was shown in **[Table 5](#pone.0147817.t005){ref-type="table"}.** In PSS, group effect (IBS vs. controls) was significant in six haplotypes. However, there was no group effect in other psychological scales. Haplotype effect was significant in all psychological scales. In STAI (trait), there was a significant group × haplotype interaction (*P* = 0.021). The four haplotype carriers (T-T-T-T, C-T-T-T, C-C-T-T, and T-C-T-T) were all the same individuals.

10.1371/journal.pone.0147817.t005

###### Psychological state and *CRHR2* SNPs in IBS patients and controls.

![](pone.0147817.t005){#pone.0147817.t005g}

  Haplotype                                   IBS vs. controls (*P* value)   haplotype effect (*P* value)   group-haplotype interaction (*P* value)
  ------------------------------------------- ------------------------------ ------------------------------ -----------------------------------------
  PSS                                                                                                       
  rs4722999---rs2267710                                                                                     
  TTTC                                        0.047                          0.035                          ns
  TTTT[\*](#t005fn002){ref-type="table-fn"}   0.041                          0.005                          ns
  CTTT[\*](#t005fn002){ref-type="table-fn"}   0.041                          0.005                          ns
  CCTT[\*](#t005fn002){ref-type="table-fn"}   0.041                          0.005                          ns
  TCTT[\*](#t005fn002){ref-type="table-fn"}   0.041                          0.005                          ns
  CTTC                                        0.047                          0.035                          ns
  CTCC                                        ns                             0.041                          ns
  CCCT                                        ns                             0.014                          ns
  STAI (state)                                                                                              
  rs4722999---rs2267710                                                                                     
  TTTC                                        ns                             0.035                          ns
  TTTT[\*](#t005fn002){ref-type="table-fn"}   ns                             0.020                          ns
  CTTT[\*](#t005fn002){ref-type="table-fn"}   ns                             0.020                          ns
  CCTT[\*](#t005fn002){ref-type="table-fn"}   ns                             0.020                          ns
  TCTT[\*](#t005fn002){ref-type="table-fn"}   ns                             0.020                          ns
  CTTC                                        ns                             0.035                          ns
  STAI (trait)                                                                                              
  rs4722999---rs2267710                                                                                     
  TTTT[\*](#t005fn002){ref-type="table-fn"}   ns                             0.020                          ns
  CTTT[\*](#t005fn002){ref-type="table-fn"}   ns                             0.020                          ns
  CCTT[\*](#t005fn002){ref-type="table-fn"}   ns                             0.020                          ns
  TCTT[\*](#t005fn002){ref-type="table-fn"}   ns                             0.020                          ns
  rs2284217---rs2284220                                                                                     
  GG                                          ns                             ns                             0.021
  SDS                                                                                                       
  rs4722999---rs2267710                                                                                     
  TTTT[\*](#t005fn002){ref-type="table-fn"}   ns                             0.012                          ns
  CTTT[\*](#t005fn002){ref-type="table-fn"}   ns                             0.012                          ns
  CCTT[\*](#t005fn002){ref-type="table-fn"}   ns                             0.012                          ns
  TCTT[\*](#t005fn002){ref-type="table-fn"}   ns                             0.012                          ns

Data without significance were not shown.

\*: The four haplotype carriers (T-T-T-T, C-T-T-T, C-C-T-T, and T-C-T-T) were all the same individuals.

Discussion {#sec013}
==========

The present study is the first to show an association between IBS and SNPs/haplotypes of the *CRHR2* gene in the Japanese population. These data suggest that *CRHR2* gene polymorphisms and haplotypes are related to the pathophysiology of IBS.

Loss of CRHR2 leads to increased inflammation, delayed healing, and exacerbates the inflammatory insult \[[@pone.0147817.ref047]--[@pone.0147817.ref049]\]. Akiba et al. reported that peripheral CRHR2 activation induces colonic hyperemia through nitric oxide synthesis without involving prostaglandin synthesis or sensory nerve activation and may protect the colonic mucosa \[[@pone.0147817.ref050]\]. In a recent study, low grade inflammation was observed in the colonic mucosa of IBS patients \[[@pone.0147817.ref051]\]. We found that *rs4722999* and *rs3779250* were positively associated with IBS in terms of genotype frequency. Especially, for both SNPs, CT carriers were observed significantly more often in IBS patients. Ishitobi et al. investigated the association of six SNPs of *CRHR2* with MDD and panic disorder \[[@pone.0147817.ref036]\]. They reported that *rs3779250* was associated with MDD, but *rs4722999* and the other SNPs were not \[[@pone.0147817.ref036]\]. In this study, major allele carriers were observed frequently in MDD patients. Similarly, in our study, the frequency of the major allele of *rs3779250* was significantly different between the patients and controls. Like IBS, MDD is worsened by psychosocial stress with dysfunction of the HPA axis. From these results, the major allele of *rs3779250* may be a risk allele for stress-related diseases. However, the C allele of *rs3779250* is observed in approximately 77% of the normal population. Therefore, the increased frequency of the major allele of *rs3779250* alone cannot explain the relationship between *CRHR2* SNPs and IBS. Further study of other factors (e.g., other genetic polymorphisms) of IBS is required.

In this study, there was no significant difference in perceived stress, anxiety, and depression between the IBS patients and controls. Our previous report \[[@pone.0147817.ref052]\] and the results of others \[[@pone.0147817.ref053]\] showed that these factors are higher in IBS patients than in controls. By contrast, IBS patients were found to be neither depressive nor anxious in another study from our laboratory \[[@pone.0147817.ref054]\]. Therefore, IBS patients in this study were psychologically close to normal, but were physically stressed. This notion is supported by the fact that statistical analysis of stress, anxiety, and depression including *CRHR2* genotypes with group (IBS patients vs. controls) showed significant differences. The relatively complex association between genotypes and IBS suggests a modifying role for CRHR2 in the pathophysiology of stress.

In seven SNP which we selected, six SNPs are in the intronic region. Only rs2240403 is in the exon region, but it is the synonymous SNP which does not cause amino acid substitution. In this study, there were significant differences in the genotype distribution of both groups in rs472299 and rs377950. In addition, there were significant interaction in association between genotype and group (IBS patients vs. controls) in psychological condition in rs2190242 and rs2284220. These SNPs are in intronic region, and the domain is spliced during transcription to mRNA. Therefore those SNPs are less likely to have an influence on the receptor expression directly. However, the SNPs influencing modulation of the psychological condition that is in vicinity of these SNP in the linkage disequilibrium in IBS may exist.

We found a haplotype of four SNPs (*rs4722999*, *rs3779250*, *rs2240403*, and *rs2267710*) and two SNPs (*rs2284217* and *rs2284220*) in strong LD (D′ \> 0.90). In this study, SNPs and haplotypes of the *CRHR2* gene were significantly different between IBS patients and controls. Sato et al. reported that genetic polymorphisms and T-A-T haplotypes of *CRHR1* mediate IBS and related bowel patterns \[[@pone.0147817.ref037]\]. Guillaume et al. reported that childhood sexual abuse and childhood emotional neglect interacted with *CRHR1* and *CRHR2* gene polymorphisms, respectively, to modulate adult decision-making in a cohort of suicide attempters \[[@pone.0147817.ref055]\]. Mahajan et al. reported that the balanced and coordinated expression of CRHR1 and CRHR2 is required for the proper regulation of urocortins in a rodent model of Crohn\'s colitis \[[@pone.0147817.ref056]\]. Therefore, haplotypes of both *CRHR1* and *CRHR2* may be related to the features of IBS.

We found that the psychological state varied from *CRHR2* genotypes and haplotypes in IBS patients and controls. Especially, we discovered that the group with one of four haplotypes (T-T-T-T, C-T-T-T, C-C-T-T, and T-C-T-T) in *CRHR2* showed a significantly lower score in perceived stress, anxiety, and depression in comparison with the group that did not have one of these haplotypes. In these four haplotypes, the common part is the T-T haplotype that consists of the T allele of rs2240403 and T allele of rs2267710. From this finding, it is suggested that having both these T alleles acts protectively against perceived stress and anxiety. To the best of our knowledge, this analysis of these four haplotypes of the *CRHR2* gene has not been performed before \[[@pone.0147817.ref035], [@pone.0147817.ref036]\]. This is a novel finding and further studies investigating the association between the T-T haplotype and other stress-related disorders are warranted.

This study has several limitations. First, the sample size was relatively small. Particularly, there were small numbers of subjects with the minor allele of *rs2240403* and the data had a wide standard error. However, our study has the strength of a higher precision of genome analyses than a genome-wide association study. Moreover, recently published genomic studies \[[@pone.0147817.ref057], [@pone.0147817.ref058]\] contained smaller number of participants than our study. Replication with a larger sample is necessary. Second, all subjects in this study were Japanese. Villafuerte et al. reported that the *CRHR2* gene was unlikely to be involved in the genetic liability underlying HPA axis dysfunction and mood disorders \[[@pone.0147817.ref059]\]. Therefore, there may be ethnic differences in the function of *CRHR2*. Third, the molecular biologic differences in the *CRHR2* gene polymorphisms examined in this study are not known. It is necessary to investigate any changes of function *in vivo* and behavior associated with the different *CRHR2* gene polymorphisms in the future. Despite some limitations, the present study is the first to clarify the possible importance of *CRHR2* in the pathophysiology of IBS.

In conclusion, our findings support the hypothesis that genetic polymorphisms and haplotypes of *CRHR2* are associated with IBS. Further studies of IBS and the CRH system are warranted.
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